WVE analyst estimates
Wave Life Sciences (WVE) analyst ratings, the average price target and its range, and every firm's latest call.
WVE analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 27, 2026 | Leerink Partners | Wave Life Sciences price target lowered to $10 from $12 at Leerink | $10.00 |
| Oct 15, 2026 | UBS | Wave Life Sciences initiated with a Buy at UBS | $11.00 |
| Oct 2, 2026 | Wedbush | H.C. Wainwright Reiterates Buy Rating on WAVE Life Sciences (WVE) | $13.00 |
| Aug 3, 2026 | UBS | H.C. Wainwright Reiterates Buy Rating on WAVE Life Sciences (WVE) | $13.00 |
| Jul 31, 2026 | Wedbush | Wave Life Sciences price target lowered to $12 from $15 at Wedbush | $12.00 |
| Jun 11, 2026 | New Street | H.C. Wainwright Reiterates Buy Rating on WAVE Life Sciences (WVE) | $13.00 |
| May 20, 2026 | Wells Fargo | Wave Life Sciences price target raised to $14 from $13 at Wells Fargo | $14.00 |
| May 19, 2026 | H.C. Wainwright | Wave Life Sciences price target lowered to $13 from $18 at H.C. Wainwright | $13.00 |
| Apr 29, 2026 | Truist Financial | Wave Life Sciences assumed with a Buy at Truist | $15.00 |
| Apr 14, 2026 | H.C. Wainwright | Wave Life Sciences price target lowered to $18 from $30 at H.C. Wainwright | $18.00 |
| Mar 27, 2026 | Wells Fargo | Wave Life Sciences price target lowered to $13 from $27 at Wells Fargo | $13.00 |
| Mar 26, 2026 | Jefferies | Wave Life Sciences price target lowered to $18 from $28 at Jefferies | $18.00 |
| Feb 12, 2026 | Wells Fargo | Wave Life Sciences price target lowered to $27 from $29 at Wells Fargo | $27.00 |
| Feb 3, 2026 | Canaccord Genuity | Wave Life Sciences price target raised to $43 from $40 at Canaccord | $43.00 |
| Feb 2, 2026 | Raymond James | Raymond James: 'WVE regains full economic rights to WVE-006 from GSK' | $26.00 |
- 17 firms rate WVE: 16 buy, 1 hold, 0 sell.
- The average price target is $12.33 from 6 analysts, from $10.00 to $14.00.
Updated 2026-11-02 18:25 UTC